The notices it replaced
- Reissues: PAR-21-033 National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
- 2 steps back: PAR-18-560 National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trials Required)
Replaced by PAR-25-081.
Who won it before
216 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $129,412,466 in first-year total cost, median $623,000.
Most frequent study sections
- Clinical Oncology Study Section[CONC]106
- Imaging Guided Interventions and Surgery Study Section[IGIS]17
- Radiation Therapeutics and Biology Study Section[RTB]14
- Developmental Therapeutics Study Section[DT]10
- Imaging Probes and Contrast Agents Study Section[IPCA]9
Most frequent institutions
- SLOAN-KETTERING INST CAN RESEARCH17
- BECKMAN RESEARCH INSTITUTE/CITY OF HOPE16
- UNIVERSITY OF TX MD ANDERSON CAN CTR16
- OHIO STATE UNIVERSITY12
- WASHINGTON UNIVERSITY12
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Fluorescence guided nerve sparing during colorectal cancer surgery using local application of a near infrared nerve fluorophore1R01CA303975-01 | ALANI, ADAM G.GIBBS, SUMMER LYNNE | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $2,491,138 | IGIS |
| 2025 | Advancing next-generation CAR-NK therapies targeting CD5 positive T cell malignancies to the clinic1R01CA303579-01 | BASAR, RAFETDAHER, MAYREZVANI, KATY | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $1,847,485 | CIC |
| 2025 | A personalized approach using hypoxia resolution to guide curative-intent radiation dose reduction to 30 Gy: A novel de-escalation paradigm for HPV-associated oropharynx cancers2R01CA238392-06 | LEE, NANCY Y | SLOAN-KETTERING INST CAN RESEARCH, NY | $777,228 | ZRG1 |
| 2025 | CMV-specific CD19 CAR T cells amplified in vivo using CMV Triplex vaccine for B-NHL1R01CA296280-01 | NAKAMURA, RYOTAROWANG, XIULI | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $738,698 | CONC |
| 2025 | Anti-CD38 Radioimmunotherapy and Total Marrow Irradiation for Treatment of Relapsed and Refractory Acute Myelogenous Leukemia1R01CA292596-01A1 | SHIVELY, JOHN ERNESTWONG, JEFFREY Y | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $738,698 | RTB |
| 2025 | Improving CDK4/6 inhibition therapy for patients with liposarcoma by understanding resistance1R01CA296835-01A1 | ANTONESCU, CRISTINA RTAP, WILLIAM D. | SLOAN-KETTERING INST CAN RESEARCH, NY | $727,732 | ATA |
| 2025 | DLL3-targeted IL18-secreting CAR T cells in Small Cell Lung Cancer1R01CA303470-01 | SCHOENFELD, ADAM J | SLOAN-KETTERING INST CAN RESEARCH, NY | $716,521 | CONC |
| 2025 | Synergistic immune response after EphrinB2 inhibition & PD-1 antibody therapy in urothelial carcinoma.1R01CA293348-01A1 | SADEGHI, SARMAD | UNIVERSITY OF SOUTHERN CALIFORNIA, CA | $712,735 | CONC |
| 2025 | Placebo-Controlled Phase II Randomized Clinical Trial of Photobiomodulation Therapy in Head and Neck Cancer Survivors with Chronic Lymphedema1R01CA289307-01A1 | DENG, JIELIN, ALEXANDERMURPHY, BARBARA A. | UNIVERSITY OF PENNSYLVANIA, PA | $706,669 | CONC |
| 2025 | Early phase clinical trials of 211At-meta-astatobenzylguanidine for children with neuroblastoma and adults with advanced neuroendocrine cancers1R01CA300202-01 | NARAYAN, VIVEK | UNIVERSITY OF PENNSYLVANIA, PA | $695,205 | RTB |
| 2025 | Pharmacodynamically directed targeted therapy for leukemia1R01CA292084-01A1 | BYRD, JOHN C.COSS, CHRISTOPHER C.HERTLEIN, ERIN KMIMS, ALICE SCOTT | UNIVERSITY OF CINCINNATI, OH | $683,472 | ATA |
| 2025 | Prognostic and Therapeutic Roles of Voltage Gated Potassium Channels in Managing KIT Mutant Gastrointestinal Stromal Tumors (GIST)1R01CA292590-01A1 | SICKLICK, JASON KEITH | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $662,682 | CONC |
| 2025 | Tumor-Selective Radiosensitization by Targeting Hypoxia in Rectal Cancer1R01CA297752-01 | WILLIAMS, TERENCE MARQUES | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $662,096 | ZRG1 |
| 2025 | Clinical Translation of a Choline-targeted NIR dye to guide lung cancer resection1R01CA293595-01A1 | DELIKATNY, EDWARD JSINGHAL, SUNIL | UNIVERSITY OF PENNSYLVANIA, PA | $657,168 | IPCA |
| 2025 | NT-I7, a novel long-acting interleukin-7, in combination with anti-PD-1 checkpoint blockade for the treatment of glioablastoma1R01CA288862-01A1 | CAMPIAN, JIAN | MAYO CLINIC ROCHESTER, MN | $639,004 | CONC |
| 2025 | Dual-tracer multiparametric imaging with a long-axial field-of-view PET to better characterize cancer1R37CA291948-01A1 | PANTEL, AUSTIN | UNIVERSITY OF PENNSYLVANIA, PA | $597,766 | CTIS |
| 2025 | Optimization of an active mutant KRAS peptide vaccine in colorectal cancer1R01CA296410-01 | AZAD, NILOFER S.ZAIDI, NEEHA | JOHNS HOPKINS UNIVERSITY, MD | $589,838 | CONC |
| 2025 | Phase 1/2 trial of PEP-CMV + nivolumab for newly diagnosed diffuse midline glioma/high-grade glioma and recurrent diffuse midline glioma/high-grade glioma, medulloblastoma, and ependymoma (PRiME II)1R01CA296813-01 | THOMPSON, ERIC | WASHINGTON UNIVERSITY, MO | $553,167 | CONC |
| 2025 | Targeting PD-L1 interactome signaling to enhance immunotherapy efficacy in head and neck squamous cell cancer2R01CA149456-11A1 | JIMENO, ANTONIO | UNIVERSITY OF COLORADO DENVER, CO | $528,427 | CONC |
| 2025 | A New Ultrasound Probe and Robot for Prostate Biopsy and Focal Therapy1R01CA303859-01 | STOIANOVICI, DAN | JOHNS HOPKINS UNIVERSITY, MD | $512,728 | IGIS |
| 2025 | Targeting the Epidermal Growth Factor Receptor (EGFR) to Revert Trastuzumab Deruxtecan Resistance in HER2-low Colorectal Cancer.1R01CA296285-01A1 | CHANDARLAPATY, SARATYAEGER, RONA | SLOAN-KETTERING INST CAN RESEARCH, NY | $482,236 | CONC |
| 2025 | B7-H3 CAR T cells following initial radiation for children and young adults with diffuse intrinsic pontine glioma1R37CA289981-01A1 | VITANZA, NICHOLAS A | SEATTLE CHILDREN'S HOSPITAL, WA | $456,414 | CONC |
| 2025 | Therapeutic targeting of the tumor microenvironment in triple negative breast cancer patients at high risk of relapse and preclinical models of lung metastases1R01CA290013-01A1 | MITTAL, VIVEKVAHDAT, LINDA THERESA | DARTMOUTH-HITCHCOCK CLINIC, NH | $442,343 | CONC |
| 2025 | Improving immune modulation for smoldering myeloma1R01CA289978-01A1 | DHODAPKAR, MADHAV V | EMORY UNIVERSITY, GA | $32,666 | CONC |
| 2024 | The Effectiveness of Automated Multimodal Imaging in High Grade Squamous Intraepithelial Lesions (HSIL) Diagnosis for People Living with HIV: An International Trial2R01CA232890-06A1 · under PAR-21-033 | ANANDASABAPATHY, SHARMILACHIAO, ELIZABETH Y. | BAYLOR COLLEGE OF MEDICINE, TX | $988,950 | ZRG1 |
| 2024 | Augmenting PSMA expression to enhance PSMA directed therapeutic efficacy1R37CA286450-01 · under PAR-21-033 | HAFFNER, MICHAEL CSCHWEIZER, MICHAEL T | FRED HUTCHINSON CANCER CENTER, WA | $720,165 | RTB |
| 2024 | Characterizing the theranostic potential of DLL3-targeting agents in high-grade neuroendocrine carcinomas of the lung and prostate1R01CA286918-01A1 · under PAR-21-033 | BODEI, LISA | SLOAN-KETTERING INST CAN RESEARCH, NY | $704,422 | IPCA |
| 2024 | ESCAPE - Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate Cancer1R37CA282407-01A1 · under PAR-21-033 | MCCLURE, TIMOTHYNAGAR, HIMANSHU | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $698,716 | IGIS |
| 2024 | Interstitial Photodynamic Therapy Following Palliative Radiotherapy for Patients with Inoperable Malignant Central Airway Obstruction1R01CA283547-01A1 · under PAR-21-033 | BUSCH, THERESA MIVANICK, NATHANIEL TSHAFIRSTEIN, GAL | ROSWELL PARK CANCER INSTITUTE CORP, NY | $698,487 | RTB |
| 2024 | Novel PET Imaging to Guide Therapy in Hepatocellular Carcinoma1R01CA279467-01A1 · under PAR-21-033 | MANNING, HENRY CHARLES | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $678,515 | IGIS |
| 2024 | Targeting non-small cell lung cancer cells and the adverse tumor microenvironment with a small-molecule STAT3 inhibitor1R01CA279452-01A1 · under PAR-21-033 | MOGHADDAM, SEYED JAVAD MIRHASSANISKOULIDIS, FERDINANDOSTWEARDY, DAVID JOHN | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $672,297 | CONC |
| 2024 | DCE-MRI guided Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer1R01CA290435-01 · under PAR-21-033 | EL-RAYES, BASSELKIM, HARRISONMASOOD, ASHIQ | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $669,747 | IGIS |
| 2024 | Neoadjuvant Immunotherapy Platform Study Reveals Mechanisms of Response in Hepatocellular Carcinoma (HCC)1R01CA285544-01A1 · under PAR-21-033 | HO, WON JINYARCHOAN, MARK | JOHNS HOPKINS UNIVERSITY, MD | $662,037 | CONC |
| 2024 | Mutant KRAS targeted vaccines for the interception of pancreatic cancer development1R37CA292056-01 · under PAR-21-033 | ZAIDI, NEEHA | JOHNS HOPKINS UNIVERSITY, MD | $659,090 | CONC |
| 2024 | Imaging tumor-associated macrophages in head and neck squamous cell carcinoma using fluorine-19 MRI1R01CA290014-01 · under PAR-21-033 | AHRENS, ERIC T.CALIFANO, JOSEPH A | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $655,700 | IPCA |
| 2024 | Causes and Consequences of Adenosine Signaling in Pancreatic Cancer1R01CA290888-01A1 · under PAR-21-033 | DONAHUE, TIMOTHY RRADU, CAIUS GABRIELWAINBERG, ZEV A | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $653,452 | CONC |
| 2024 | Bioactivity of CAR T cells secreting T cell engager-anitbodies in humans with glioblastoma1R01CA294071-01A1 · under PAR-21-033 | CHOI, BRYANMAUS, MARCELA VALDERRAMA | MASSACHUSETTS GENERAL HOSPITAL, MA | $652,725 | CNBT |
| 2024 | Phase 1 First in Human Trial to Assess Safety and Tolerability of the Novel ACK1 Inhibitor (R)-9b in Patients with Prostate Cancer1R01CA286443-01A1 · under PAR-21-033 | MAHAJAN, KIRANMAHAJAN, NUPAM P | WASHINGTON UNIVERSITY, MO | $652,414 | CONC |
| 2024 | Targeting GARP-TGFbeta for Immunotherapy of Non-Small Cell Lung Cancer1R01CA282501-01A1 · under PAR-21-033 | LI, ZIHAI | OHIO STATE UNIVERSITY, OH | $641,336 | CONC |
| 2024 | Targeted EGFR for basal subtype pancreatic cancer1R01CA288145-01 · under PAR-21-033 | JOHNSON, GARY L.YEH, JEN JEN | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $639,879 | CONC |
| 2024 | Accelerated Brachytherapy Forward Chemoradiation Therapy (ABC-RT) for Cervical Cancer1R37CA287204-01A1 · under PAR-21-033 | CONTRERAS, JESSIKAMARKOVINA, STEPHANIE | WASHINGTON UNIVERSITY, MO | $634,894 | CONC |
| 2024 | Fecal microbial transplantation for chemotherapy behavioral side effects1R01CA287261-01 · under PAR-21-033 | PYTER, LEAH M | OHIO STATE UNIVERSITY, OH | $615,068 | CNBT |
| 2024 | Radiation and dendritic cell combination to improve immunotherapy response in intrahepatic cholangiocarcinoma1R01CA294704-01 · under PAR-21-033 | LIN, YIPARK, SEAN SROBERTS, LEWIS R | MAYO CLINIC ROCHESTER, MN | $610,890 | ZRG1 |
| 2024 | ProAgio in Pancreatic Cancer1R01CA294647-01 · under PAR-21-033 | EL-RAYES, BASSELLIU, ZHI-REN | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $590,094 | ZRG1 |
| 2024 | Leveraging CD26high Meso-CAR T cells in patients with advanced pancreatic cancer1R01CA287866-01 · under PAR-21-033 | LESINSKI, GREGORY B.PAULOS, CHRYSTAL MARYWALLER, EDMUND K | EMORY UNIVERSITY, GA | $575,241 | CONC |
| 2024 | HER2 PET imaging to assess HER2 heterogeneity and predict response to HER2-targeted ADC therapy in urothelial carcinoma1R01CA288692-01 · under PAR-21-033 | IYER, GOPASOLIT, DAVID B.YEH, RANDY | SLOAN-KETTERING INST CAN RESEARCH, NY | $556,681 | IGIS |
| 2024 | A translational study of a synthetic lethality interaction of CD105 and androgen receptor signaling axis for castration-resistant prostate cancer patients1R01CA292654-01 · under PAR-21-033 | BHOWMICK, NEIL A.POSADAS, EDWIN MELENCIO | CEDARS-SINAI MEDICAL CENTER, CA | $553,550 | CONC |
| 2024 | Assessing Metabolically Reprogrammed and Purified CD19-CAR-T in NHL and CLL1R01CA282408-01A1 · under PAR-21-033 | HESS, BRIANMEHROTRA, SHIKHAR | MEDICAL UNIVERSITY OF SOUTH CAROLINA, SC | $533,348 | CONC |
| 2024 | Addressing tumor heterogeneity in pediatric gliomas with precision adoptive T cell therapy1R01CA293376-01 · under PAR-21-033 | MITCHELL, DUANE A. | UNIVERSITY OF FLORIDA, FL | $474,656 | CNBT |
| 2024 | Targeting mitochondrial calcium to eradicate leukemia-initiating cells1R01CA292071-01 · under PAR-21-033 | JORDAN, CRAIG T.POLLYEA, DANIEL A | UNIVERSITY OF COLORADO DENVER, CO | $437,432 | ATA |
| 2024 | Neoadjuvant Tucatinib plus Trastuzumab in HER2-amplified Locally Advanced Rectal Cancer1R01CA288880-01 · under PAR-21-033 | CERCEK, ANDREAYAEGER, RONA | SLOAN-KETTERING INST CAN RESEARCH, NY | $402,600 | CONC |
| 2024 | Evaluation of combination CLK/DYRK (Cirtuvivint) inhibition with PARP inhibition (Olaparib) in BRCA/HRD platinum resistant ovarian cancer1R01CA288651-01 · under PAR-21-033 | CORR, BRADLEY | UNIVERSITY OF COLORADO DENVER, CO | $400,444 | CONC |
| 2024 | TROP2-Directed CAR-NK Cells for the Immunotherapy of Pancreatic Cancer1R01CA288617-01 · under PAR-21-033 | BASAR, RAFETRAFEI, HINDREZVANI, KATY | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $370,575 | CIC |
| 2024 | Secondary Molecular Imaging (SMI) for head and neck cancer1R01CA279249-01A1 · under PAR-21-033 | ROSENTHAL, EBEN L. | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $338,740 | IGIS |
| 2023 | EBNA1 Inhibitor for Treatment of EBV-positive DLBCL1R01CA282411-01 · under PAR-21-033 | LIEBERMAN, PAUL M.MESSICK, TROY EPORCU, PIERLUIGI | WISTAR INSTITUTE, PA | $745,842 | MCDC |
| 2023 | A randomized controlled phase 2 study of the ketogenic diet for patients with newly diagnosed glioblastoma in combination with standard-of-care treatment1R01CA276919-01 · under PAR-21-033 | FREEDLAND, STEPHEN JAYHU, JETHRO | CEDARS-SINAI MEDICAL CENTER, CA | $739,138 | CPSS |
| 2023 | Deciphering the Acidic Tumor Environment: A Phase I/IIa Study of Pre-Operative Multiparametric MRI and pHLIP® ICG Intra-Operative Fluorescence Imaging of Primary Breast Cancer1R01CA270018-01A1 · under PAR-21-033 | MORROW, MONICAPINKER-DOMENIG, KATJA | SLOAN-KETTERING INST CAN RESEARCH, NY | $706,536 | IGIS |
| 2023 | Intensive cholesterol-lowering intervention and anti-tumor immunity modeled in prostate cancer1R01CA280060-01A1 · under PAR-21-033 | KIM, HYUNG LTHOMPSON, PATRICIA ANN | CEDARS-SINAI MEDICAL CENTER, CA | $692,001 | CPSS |
| 2023 | Transfer of vaccine-induced immunity from immunocompetent stem cell donor as antiviral immunotherapy to protect high-risk transplant recipients from cytomegalovirus reactivation1R01CA266783-01A1 · under PAR-21-033 | DIAMOND, DON J | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $688,080 | CONC |
| 2023 | A single-arm phase II study to evaluate the safety and efficacy of combination systematic chemotherapy and multiple rounds of endoscopic ultrasound-guided radiofrequency ablation in pancreatic cancer1R01CA277161-01A1 · under PAR-21-033 | LUNDBERG, JENNIFER BAILEYTHOSANI, NIRAV | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON, TX | $676,081 | CONC |
| 2023 | Modulating the PD-1/PD-L1 checkpoint to promote antitumor activity of HER2 CAR T cells in patients with sarcoma1R01CA276684-01 · under PAR-21-033 | HEGDE, MEENAKSHI G | BAYLOR COLLEGE OF MEDICINE, TX | $667,761 | CONC |
| 2023 | A novel molecularly targeted theranostic approach via the alphavbeta6 integrin for the detection and treatment of metastatic cancers1R01CA279342-01 · under PAR-21-033 | FOSTER, CAMERON CARLSUTCLIFFE, JULIE L | UNIVERSITY OF CALIFORNIA AT DAVIS, CA | $664,690 | CTIS |
| 2023 | Combining immunotherapy with molecularly targeted radiation therapy1R01CA276785-01A1 · under PAR-21-033 | AGGARWAL, RAHULEVANS, MICHAEL JOHNFONG, LAWRENCE | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $663,343 | CONC |
| 2023 | Sonobiopsy for Noninvasive Genetic Evaluation of Glioblastoma Patients1R01CA276174-01 · under PAR-21-033 | CHEN, HONGLEUTHARDT, ERIC CLAUDE | WASHINGTON UNIVERSITY, MO | $651,157 | CBSS |
| 2023 | Neoadjuvant immunoradiotherapy for HPV mediated oropharynx cancer1R01CA281286-01 · under PAR-21-033 | CALIFANO, JOSEPH A | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $644,774 | ZRG1 |
| 2023 | Effects of Arginine Depletion Combined with Platinum-Taxane Chemotherapy in Aggressive Variant Prostate Cancers (AVPC)1R01CA283402-01 · under PAR-21-033 | APARICIO, ANAFRIGO, DANIEL EDWARDSHARMA, PADMANEE | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $636,578 | CONC |
| 2023 | A phase I/II study of combined therapy with Th17-inducing dendritic cells and pembrolizumab in patients with recurrent epithelial ovarian cancer1R01CA276313-01 · under PAR-21-033 | BLOCK, MATTHEW STEPHENKNUTSON, KEITH L. | MAYO CLINIC JACKSONVILLE, FL | $634,953 | CONC |
| 2023 | Exercise as an Immune Adjuvant for Gamma Delta T-cell Therapies in Hematologic Malignancies1R01CA277493-01 · under PAR-21-033 | KATSANIS, EMMANUELSIMPSON, RICHARD J | UNIVERSITY OF ARIZONA, AZ | $630,619 | CPSS |
| 2023 | Irreversible Electroporation (IRE) Combined with CD40 Agonism as In Situ Vaccine Therapy for Pancreatic Cancer1R01CA282439-01 · under PAR-21-033 | SCHOENBERGER, STEPHEN PHILIPWHITE, REBEKAH | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $629,181 | CONC |
| 2023 | Personalized vaccine immunotherapy in combination with anti-PD 1 antibody for recurrent or metastatic squamous cell carcinoma of the head and neck1R01CA262123-01A1 · under PAR-21-033 | SELVARAJ, PERIASAMYSHIN, DONG M | EMORY UNIVERSITY, GA | $625,507 | CONC |
| 2023 | Intravenous VSV virotherapy in lymphoma1R01CA262613-01A1 · under PAR-21-033 | BENNANI, NABILA NORAPENG, KAH-WHYE | MAYO CLINIC ROCHESTER, MN | $619,753 | DT |
| 2023 | Quantitative molecular MR-PET imaging of glycolysis in glioblastoma1R01CA279984-01 · under PAR-21-033 | ELLINGSON, BENJAMIN M.NATHANSON, DAVID A. | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $619,045 | MCDC |
| 2023 | AI-Assisted Microendoscopy for the Early Detection of Esophageal Cancer2R01CA181275-07 · under PAR-21-033 | ANANDASABAPATHY, SHARMILA | BAYLOR COLLEGE OF MEDICINE, TX | $612,665 | IGIS |
| 2023 | Trispecific CAR-T cells targeting CD19, CD20 and CD22 to treat B-cell malignancies1R01CA276374-01A1 · under PAR-21-033 | ALINARI, LAPODE LIMA, MARCOSVASU, SUMITHIRA | OHIO STATE UNIVERSITY, OH | $609,273 | CONC |
| 2023 | Development of contrast agents to facilitate image-guided surgery1R01CA281098-01A1 · under PAR-21-033 | JAIN, AJAYMCNALLY, LACEY R | UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR, OK | $607,029 | IPCA |
| 2023 | A Phase II Clinical Trial in Newly Diagnosed Glioblastoma Patients Treated with WP1066 and Radiation1R01CA272639-01A1 · under PAR-21-033 | HEIMBERGER, AMY BETHKUMTHEKAR, PRIYA U. | NORTHWESTERN UNIVERSITY AT CHICAGO, IL | $601,792 | CONC |
| 2023 | Novel synthetic lethality strategy for TP53 mutant colorectal cancer1R37CA282430-01 · under PAR-21-033 | FOUNTZILAS, CHRISTOS | ROSWELL PARK CANCER INSTITUTE CORP, NY | $585,984 | MCTA |
| 2023 | Immune Therapy for Brain Metastasis1R01CA269286-01A1 · under PAR-21-033 | JILAVEANU, LUCIA BEATRICEKLUGER, HARRIET M. | YALE UNIVERSITY, CT | $583,091 | CONC |
| 2023 | Glioma intelligence from behind enemy lines1R37CA276851-01 · under PAR-21-033 | BURNS, TERRY | MAYO CLINIC ROCHESTER, MN | $545,993 | DT |
| 2023 | Targeting Tryptophan Metabolism in Rectal Cancer1R01CA278197-01A1 · under PAR-21-033 | CIORBA, MATTHEW AARONPARK, HAESEONG | WASHINGTON UNIVERSITY, MO | $513,828 | MCDC |
| 2023 | Neoadjuvant Neratinib in Stage I-III HER2-mutated Lobular Breast Cancer1R01CA273246-01A1 · under PAR-21-033 | ARTEAGA, CARLOS LKENNEDY, LAURA CARPIN | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $510,310 | CONC |
| 2023 | Toward Clinical Trial: AXL-STAT3 Targeting of Lung Tumor Microenvironments1R01CA269766-01A1 · under PAR-21-033 | TAVERNA, JOSEPHINE A | UNIVERSITY OF TEXAS HLTH SCIENCE CENTER, TX | $478,705 | CONC |
| 2023 | Targeting PLK1 in RAS mutant chronic myelomonocytic leukemia1R01CA272496-01A1 · under PAR-21-033 | PATNAIK, MRINAL SHIV | MAYO CLINIC ROCHESTER, MN | $427,131 | CONC |
| 2023 | Next Generation Engineered NK Cells for Lymphoma Patients after CD19 CAR-T Cell Failure.1R01CA280827-01 · under PAR-21-033 | BASAR, RAFETDAHER, MAYREZVANI, KATY | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $370,575 | CIC |
| 2023 | Defining Optimal Radiotherapy Dose and Fractionation in Combination with Preoperative Immuno-Chemotherapy in Early-Stage Triple Negative Breast Cancer1R01CA274254-01 · under PAR-21-033 | DUDA, DAN GABRIELGUPTA, GAORAV P.HO, ALICE | DUKE UNIVERSITY, NC | $1 | RTB |
| 2022 | Enhancing B7-H3-CAR T cell therapy for pediatric solid tumors1R01CA262589-01A1 · under PAR-21-033 | DERENZO, CHRISTOPHER C.GOTTSCHALK, STEPHEN | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, TN | $734,126 | CONC |
| 2022 | Neoantigen-specific T cell responses for Fibrolamellar Hepatocellular Carcinoma1R01CA265009-01A1 · under PAR-21-033 | THOMAS, PAUL G.YARCHOAN, MARK | JOHNS HOPKINS UNIVERSITY, MD | $733,308 | ZRG1 |
| 2022 | Engineered anti-PSCA antibodies for immunoPET and targeted therapy of pancreatic cancer1R01CA266665-01 · under PAR-21-033 | WU, ANNA M | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $729,981 | IPCA |
| 2022 | A Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T cells Targeting TAG72 in Patients with Recurrent Epithelial Ovarian Cancer1R01CA266874-01A1 · under PAR-21-033 | PRICEMAN, SAULRODRIGUEZ-RODRIGUEZ, LORNA | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $723,036 | CONC |
| 2022 | Intracerebroventricular (ICV) Administration of CD19-Targeting Chimeric Antigen Receptor (CAR) T cells for Treatment of Primary Central Nervous System Lymphoma1R01CA266611-01A1 · under PAR-21-033 | FORMAN, STEPHEN JSIDDIQI, TANYAWANG, XIULI | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $719,558 | CONC |
| 2022 | Implementation of an interventional, risk-adapted clinical trial for children with newly diagnosed juvenile myelomonocytic leukemia.1R37CA266550-01A1 · under PAR-21-033 | STIEGLITZ, ELLIOT | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $711,288 | CONC |
| 2022 | Targeting T cell dysfunction in glioblastoma: A proof-of-concept Phase 0/I trial of anti-TIGIT antibody AB154 in combination with anti-PD1 antibody AB1221R01CA266757-01 · under PAR-21-033 | HAFLER, DAVID A.OMURO, ANTONIO M | YALE UNIVERSITY, CT | $695,125 | CONC |
| 2022 | Targeting complement to enhance antitumor immunity and control malignant effusions in patients with recurrent epithelial ovarian cancer1R01CA267690-01A1 · under PAR-21-033 | SEGAL, BRAHM H.ZSIROS, EMESE | ROSWELL PARK CANCER INSTITUTE CORP, NY | $693,903 | CONC |
| 2022 | BAFF-R CAR T cell therapy for ALL1R01CA269569-01 · under PAR-21-033 | ALDOSS, IBRAHIMKWAK, LARRY WWANG, XIULI | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $677,623 | CONC |
| 2022 | Coffee and metabolites modulating the gut microbiome for improved colorectal cancer survival1R01CA263776-01A1 · under PAR-21-033 | SONG, MINGYANG | HARVARD SCHOOL OF PUBLIC HEALTH, MA | $676,076 | CPSS |
| 2022 | Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer1R01CA260902-01A1 · under PAR-21-033 | POWELL, DANIEL J. | UNIVERSITY OF PENNSYLVANIA, PA | $672,991 | ZRG1 |
| 2022 | Targeting head and neck cancer cells and the adverse tumor microenvironment with a novel small-molecule STAT3 inhibitor1R01CA269516-01 · under PAR-21-033 | JOHNSON, FAYESIKORA, ANDREWTWEARDY, DAVID JOHN | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $671,730 | DT |
| 2022 | Development of CD46 theranostics for imaging and treatment of multiple myeloma1R01CA271606-01A1 · under PAR-21-033 | FLAVELL, ROBERT RICHARDWIITA, ARUN P. | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $670,212 | IPCA |
| 2022 | Immunotherapy of Uveal Melanoma using PRAME Vaccine in Combination with Adoptive T Cell Therapy1R01CA266714-01A1 · under PAR-21-033 | PATEL, SAPNAYEE, CASSIAN | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $668,196 | CII |
| 2022 | Understanding Treatment Response Patterns And Therapy Resistance In IDH-Mutant AML1R01CA262496-01A1 · under PAR-21-033 | EISFELD, ANN-KATHRINMARDIS, ELAINE RMIMS, ALICE SCOTT | OHIO STATE UNIVERSITY, OH | $664,967 | CONC |
| 2022 | Phase 0/1 trial of ONC206 - a novel imipridone for children with diffuse midline gliomas and recurrent malignant brain tumors1R01CA266596-01A1 · under PAR-21-033 | MUELLER, SABINE | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $664,049 | CONC |
| 2022 | Receptor-Targeted Fluorescence-Guided Surgery in Pancreatic Neuroendocrine Tumors1R01CA263512-01A1 · under PAR-21-033 | AZHDARINIA, ALIIKOMA, NARUHIKO | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON, TX | $662,090 | IPCA |
| 2022 | Integrating Epigenetic Modulation into DNA Damage Repair1R01CA255613-01A1 · under PAR-21-033 | MUNSTER, PAMELA N. | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $656,890 | CONC |
| 2022 | PSMA-PET to Guide Prostatectomy: Can PSMA-PET Appropriately Modify Surgery, Reduce Nerve Damage and Optimize Quality-of-Life?1R01CA258994-01A1 · under PAR-21-033 | BAHLER, CLINTON DAVID | INDIANA UNIVERSITY INDIANAPOLIS, IN | $637,698 | IGIS |
| 2022 | IL-15 and -21 armored GPC3-specific CAR T cells for children with solid tumors1R01CA258866-01A1 · under PAR-21-033 | HECZEY, ANDRAS A. | BAYLOR COLLEGE OF MEDICINE, TX | $635,004 | CONC |
| 2022 | Combating melanoma resistance by targeting ABL1/21R01CA258751-01A1 · under PAR-21-033 | KOLESAR, JILL MARIEPLATTNER, RINAWILSON, MELISSA A | UNIVERSITY OF KENTUCKY, KY | $634,772 | CONC |
| 2022 | Radiation and dendritic cells to hepatomas to improve immunotherapy response1R01CA274985-01 · under PAR-21-033 | LIN, YIPARK, SEAN SROBERTS, LEWIS R | MAYO CLINIC ROCHESTER, MN | $632,389 | RTB |
| 2022 | Targeting polo-like kinase for therapy of small cell lung cancer1R01CA273216-01 · under PAR-21-033 | OWONIKOKO, TAOFEEK K | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $630,466 | CONC |
| 2022 | Phase 1 Evaluation of Enhanced Natural Killer Cells as a Treatment Strategy in Non-Small cell Lung Cancer Patients Refractory to PD-1/PD-L1 Immune Checkpoint Inhibitors1R01CA266457-01A1 · under PAR-21-033 | VILLALONA, MIGUEL AYU, JIANHUA | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $620,673 | CONC |
| 2022 | Use of radioprotector in rectal cancer1R01CA255618-01A1 · under PAR-21-033 | LIN, CHIOBERLEY-DEEGAN, REBECCA E | UNIVERSITY OF NEBRASKA MEDICAL CENTER, NE | $615,378 | CONC |
| 2022 | Precision Imaging of Breast Cancer for Guiding Neoadjuvant Endocrine Therapy1R01CA272571-01 · under PAR-21-033 | FOWLER, AMY | UNIVERSITY OF WISCONSIN-MADISON, WI | $605,718 | CTIS |
| 2022 | Targeting c-Myc stability in c-Myc overexpressing large B-cell lymphoma1R01CA266682-01 · under PAR-21-033 | ALINARI, LAPO | OHIO STATE UNIVERSITY, OH | $601,346 | CONC |
| 2022 | Overcoming metastatic spread of osteosarcoma with RNA loaded nanoparticles1R01CA266857-01A1 · under PAR-21-033 | SAYOUR, ELIAS | UNIVERSITY OF FLORIDA, FL | $560,034 | CONC |
| 2022 | Targeting MicroRNAs to Eradicate Leukemia Stem Cells2R01CA205247-06 · under PAR-21-033 | KUO, YA-HUEIMARCUCCI, GUIDONGUYEN, LE XUAN TRUONG | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $505,757 | DT |
| 2022 | Cooperation of the TAM and Abl family kinases in therapeutic resistance in HNC1R01CA262292-01A1 · under PAR-21-033 | SALGIA, RAVIWHEELER, DERIC L | UNIVERSITY OF WISCONSIN-MADISON, WI | $504,584 | DT |
| 2022 | Contrast Enhanced Mammography (CEM) to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study1R01CA258898-01A1 · under PAR-21-033 | ZULEY, MARGARITA L | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $471,449 | CTIS |
| 2022 | Connectivity mapping identified novel combination therapy for glioblastoma1R01CA273319-01 · under PAR-21-033 | BATRA, SURINDER K.SHONKA, NICOLE | UNIVERSITY OF NEBRASKA MEDICAL CENTER, NE | $445,918 | DT |
| 2022 | Optimizing novel agent combination therapy for previously untreated, high risk chronic lymphocytic leukemia1R01CA266298-01A1 · under PAR-21-033 | DAVIDS, MATTHEW S | DANA-FARBER CANCER INST, MA | $421,375 | CONC |
| 2022 | Novobiocin-mediated polymerase theta inhibition in homologous recombination repair-deficient cancers1R01CA272982-01 · under PAR-21-033 | SHAPIRO, GEOFFREY I | DANA-FARBER CANCER INST, MA | $414,529 | DT |
| 2022 | A Multifaceted Radiomics Model to Predict Cervical Lymph Node Metastasis for Involved Nodal Radiation Therapy1R01CA251792-01A1 · under PAR-21-033 | SHER, DAVIDWANG, JING | UT SOUTHWESTERN MEDICAL CENTER, TX | $410,620 | RTB |
| 2022 | Clinical evaluation and non-invasive monitoring of Vorasidenib in combination with tumor specific peptide PEP-IDH1M vaccine therapy in patients with recurrent mutant IDH1 glioma1R01CA271129-01 · under PAR-21-033 | PETERS, KATHERINE BSOHER, BRIAN J | DUKE UNIVERSITY, NC | $392,725 | CNBT |
| 2022 | Optimizing radiation therapy through the manipulation of glutamine metabolism2R01CA181745-06A1 · under PAR-21-033 | SCHWARZ, JULIE KRISTINA | WASHINGTON UNIVERSITY, MO | $374,063 | RTB |
| 2022 | Inhibition of T-cell Receptor Signaling for Treatment of Adult T-cell Leukemia Lymphoma1R01CA258359-01A1 · under PAR-21-033 | RATNER, LEERAUCH, DANIEL ARTHUR | WASHINGTON UNIVERSITY, MO | $360,282 | CONC |
| 2021 | Validation of epigenomic biomarkers for thyroid cancer diagnostics1R01CA241845-01A1 · under PAR-18-560 | HAHN, MARIAYIM, JOHN H | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $958,109 | CBSS |
| 2021 | Tumor Subtypes and Therapy Response in Pancreatic Cancer2R01CA199064-06A1 · under PAR-18-560 | TSAI, SUSANYEH, JEN JEN | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $806,124 | CONC |
| 2021 | Personalized Adoptive T-cell Therapy for AML1R01CA262629-01 · under PAR-18-560 | AVIGAN, DAVID E.ROSENBLATT, JACALYN | BETH ISRAEL DEACONESS MEDICAL CENTER, MA | $762,763 | CONC |
| 2021 | Understanding and Enhancing T-Cell Responses to High Risk Human Papillomaviruses-Renewal2R01CA143130-11A1 · under PAR-18-560 | NAKAGAWA, MAYUMI | UNIV OF ARKANSAS FOR MED SCIS, AR | $727,272 | CONC |
| 2021 | A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC Patients1R01CA260872-01 · under PAR-18-560 | AMIN, HESHAM MDUDA, DAN GABRIELKASEB, AHMED | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $711,171 | CONC |
| 2021 | CAR T Cells for Advanced Thyroid Cancer1R01CA254035-01A1 · under PAR-18-560 | FAHEY, THOMAS JJIN, MOONSOO M.VAN BESIEN, KOEN WALTER | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $693,091 | CONC |
| 2021 | Targeting obesity to improve survival from childhood acute lymphoblastic leukemia1R37CA252236-01A1 · under PAR-18-560 | ORGEL, ETAN | CHILDREN'S HOSPITAL OF LOS ANGELES, CA | $687,010 | CONC |
| 2021 | Developing Safe and Effective GD2-CAR T Cell Therapy for Diffuse Midline Gliomas1R01CA263500-01 · under PAR-18-560 | MACKALL, CRYSTALMONJE-DEISSEROTH, MICHELLE | STANFORD UNIVERSITY, CA | $671,445 | CONC |
| 2021 | Measuring Metabolic Activity in Prostate Cancer Bone Metastases Using Hyperpolarized 13C Pyruvate MRI for Improved Targeted Therapy Monitoring1R01CA256740-01 · under PAR-18-560 | AGGARWAL, RAHULVIGNERON, DANIEL B | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $669,448 | IGIS |
| 2021 | Overcoming Hypoxic Resistance in Non-Small Cell Lung Cancer By Targeting Mitochondrial Metabolism1R01CA262388-01 · under PAR-18-560 | DENKO, NICHOLAS C.LI, ZIHAIWILLIAMS, TERENCE MARQUES | OHIO STATE UNIVERSITY, OH | $650,406 | ZRG1 |
| 2021 | Pacritinib in rel/refr T-cell lymphomas1R01CA265929-01 · under PAR-18-560 | WILCOX, RYAN A | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $645,497 | CONC |
| 2021 | Multi-receptor Targeting of Glioblastoma1R01CA256285-01A1 · under PAR-18-560 | DEBINSKI, WALDEMAR | WAKE FOREST UNIVERSITY HEALTH SCIENCES, NC | $642,795 | CONC |
| 2021 | Serial immunotherapy combination to modulate the tumor environment in patients with metastatic gastroesophageal cancer1R01CA248147-01A1 · under PAR-18-560 | YOON, HARRY H | MAYO CLINIC ROCHESTER, MN | $640,182 | CONC |
| 2021 | Targeting KRAS and adenosine mediated immunosuppression in pancreatic cancer1R01CA260678-01 · under PAR-18-560 | DONAHUE, TIMOTHY RRADU, CAIUS GABRIELWAINBERG, ZEV A | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $634,454 | DT |
| 2021 | Targeting B7-H3 in ovarian cancer1R01CA256898-01 · under PAR-18-560 | DOTTI, GIANPIETROGEHRIG, PAOLA ALVAREZ | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $632,310 | ZRG1 |
| 2021 | A Phase 1 Trial of MLN0128 (sapanisertib) and CB-839 HCl (telaglenastat) in Advanced NSCLC Patients1R01CA255639-01A1 · under PAR-18-560 | PAIK, PAUL KRIESS, JONATHAN W | SLOAN-KETTERING INST CAN RESEARCH, NY | $628,641 | CONC |
| 2021 | Understanding and targeting MAPK pathway activation in NF1-deficient malignant peripheral nerve sheath tumor (MPNST)1U01CA252048-01A1 · under PAR-18-560 | CHI, PING | SLOAN-KETTERING INST CAN RESEARCH, NY | $622,197 | DT |
| 2021 | Phase II Clinical Development of Galectin-3 Inhibition and Anti-PD-1: Immune Monitoring and Tumor Response1R01CA255650-01A1 · under PAR-18-560 | CURTI, BRENDAN DREDMOND, WILLIAM L | PROVIDENCE PORTLAND MEDICAL CENTER, OR | $593,078 | CONC |
| 2021 | Targeting STAT3 for the Treatment of CDK4/6 Inhibitor Resistant Advanced Estrogen Receptor Positive Breast Cancer Patients1R01CA255960-01 · under PAR-18-560 | KEYOMARSI, KHANDAN | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $587,495 | CONC |
| 2021 | Training Swallowing Initiation during Expiration: Impact on Safety and Efficiency Following Treatment for Oropharyngeal Head and Neck Cancer1R01CA262502-01 · under PAR-18-560 | MARTIN-HARRIS, BONNIE J | NORTHWESTERN UNIVERSITY, IL | $586,422 | MFSR |
| 2021 | Targeting the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer with a Neoadjuvant Platform Clinical Trial2R01CA197296-06 · under PAR-18-560 | JAFFEE, ELIZABETH M.ZHENG, LEI | JOHNS HOPKINS UNIVERSITY, MD | $581,039 | CONC |
| 2021 | Targeting immunosuppressive adenosine in patients with metastatic non-small cell lung cancer1R01CA248741-01A1 · under PAR-18-560 | CARBONE, DAVID P.DIKOV, MIKHAIL M | OHIO STATE UNIVERSITY, OH | $577,069 | CONC |
| 2021 | Reduction of Tumor-Positive Margins in Oncology Surgery1R37CA245157-01A1 · under PAR-18-560 | WARRAM, JASON MORGAN | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $563,251 | CONC |
| 2021 | Targeting Nucleotide Metabolism to Overcome Therapy Resistance in Glioblastoma1R37CA258346-01 · under PAR-18-560 | WAHL, DANIEL R | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $554,870 | RTB |
| 2021 | Re-wiring PDAC Tumor Immunity Through Dendritic Cells1R01CA262506-01 · under PAR-18-560 | DENARDO, DAVID GDESELM, CARL | WASHINGTON UNIVERSITY, MO | $551,987 | CII |
| 2021 | Neoadjuvant Immunotherapy with Intratumoral CPG and PD-1 Blockade in Melanoma1R01CA257265-01 · under PAR-18-560 | DAVAR, DIWAKARZAROUR, HASSANE M | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $551,927 | CONC |
| 2021 | Molecular Pathogenesis and Therapy of Systemic Histiocytic Neoplasms1R37CA259260-01 · under PAR-18-560 | DIAMOND, ELI LOUS | SLOAN-KETTERING INST CAN RESEARCH, NY | $551,042 | CONC |
| 2021 | Targeted Therapies for Lymphoid Malignancies2R01CA177292-06A1 · under PAR-18-560 | ROGERS, KERRY ANNEWOYACH, JENNIFER A. | OHIO STATE UNIVERSITY, OH | $538,241 | CONC |
| 2021 | Novel combination therapy for AML expressing mutant RUNX11R01CA262636-01 · under PAR-18-560 | BHALLA, KAPILDINARDO, COURTNEYTAKAHASHI, KOICHI | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $534,187 | CONC |
| 2021 | Precision targeting of T cell cytotoxicity with PET1R01CA258297-01 · under PAR-18-560 | AGGARWAL, RAHULCRAIK, CHARLES SCOTTEVANS, MICHAEL JOHNFONG, LAWRENCE | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $524,205 | CTIS |
| 2021 | Repolarizing the Tumor and Metastatic Microenvironments to Treat Patients with Pancreatic Cancer1R01CA262580-01 · under PAR-18-560 | GERBER, SCOTT ANDREWLINEHAN, DAVID C | UNIVERSITY OF ROCHESTER, NY | $516,038 | CONC |
| 2021 | Targeting FLT3 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia1R01CA265095-01 · under PAR-18-560 | BUDDE, LIHUA ELIZABETHCALIGIURI, MICHAEL AYU, JIANHUA | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $489,159 | CONC |
| 2021 | Overcoming the blood-brain barrier with nanoparticle vaccines against gliomas1R37CA251978-01A1 · under PAR-18-560 | SAYOUR, ELIAS | UNIVERSITY OF FLORIDA, FL | $472,806 | CII |
| 2021 | Improving efficacy of radioiodine treatment of thyroid cancer1R01CA249663-01A1 · under PAR-18-560 | FAGIN, JAMES AHO, ALAN L. | SLOAN-KETTERING INST CAN RESEARCH, NY | $471,416 | MCE |
| 2021 | Increasing nerve-sparing radical prostatectomy rates using intraoperative nonlinear microscopy1R01CA249151-01A1 · under PAR-18-560 | FUJIMOTO, JAMES G | MASSACHUSETTS INSTITUTE OF TECHNOLOGY, MA | $466,284 | IGIS |
| 2021 | Vaccine Targeting of RCC Blood Vessels to Promote TME Normalization and Enhance TIL Recruitment1R01CA249811-01A1 · under PAR-18-560 | MARANCHIE, JODI KATHLEENSTORKUS, WALTER J. | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $456,744 | CII |
| 2021 | Interactions of Androgen Production, Uptake and Metabolism on outcome in Castration Resistant Prostate Cancer1R01CA249279-01A1 · under PAR-18-560 | HALABI, SUSANRYAN, CHARLES JAMESSHARIFI, NIMA | UNIVERSITY OF MINNESOTA, MN | $426,729 | CONC |
| 2021 | Targeting epigenetic regulation via Bromodomain and Extraterminal (BET) domain inhibition for treatment of GVHD1R01CA252469-01A1 · under PAR-18-560 | CHOE, HANNAHRANGANATHAN, PARVATHI | OHIO STATE UNIVERSITY, OH | $415,000 | CONC |
| 2021 | A First-in-Human Phase I Clinical Trial of Mitochondrial-Targeted Hsp90 Inhibitor, Gamitrinib1R01CA225913-01A1 · under PAR-18-560 | ALTIERI, DARIO COLSZANSKI, ANTHONY J. | WISTAR INSTITUTE, PA | $410,285 | CONC |
| 2021 | Robot-Assisted Personalized Prostate Biopsy1R01CA247959-01A1 · under PAR-18-560 | STOIANOVICI, DAN | JOHNS HOPKINS UNIVERSITY, MD | $316,306 | BTSS |
| 2021 | Two photon fluorescence microscopy for dermatologic surgery and biopsy1R37CA258376-01 · under PAR-18-560 | GIACOMELLI, MICHAEL GENE | UNIVERSITY OF ROCHESTER, NY | $308,061 | IGIS |
| 2020 | Clinical Evaluation of Chlorotoxin-redirected Chimeric Antigen Receptor (CAR) T cells for Treatment of Glioblastoma1R01CA254271-01 · under PAR-18-560 | BADIE, BEHNAMBROWN, CHRISTINE | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $768,221 | CONC |
| 2020 | Evaluation of an implantable microdevice for rapid cancer drug screening directly in T cell lymphoma patients1R37CA252312-01 · under PAR-18-560 | LAROCCA, CECILIA | BRIGHAM AND WOMEN'S HOSPITAL, MA | $759,496 | CONC |
| 2020 | Evaluation of Transperineal Biopsy under Local Anesthesia, a Novel approach to Decrease Post-Biopsy Infections and Improve Cancer Detection1R01CA241758-01A1 · under PAR-18-560 | ALLAF, MOHAMADHU, JIMSCHAEFFER, EDWARD MATTHEW | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $737,794 | NRCS |
| 2020 | A personalized approach using hypoxia resolution to guide curative-intent radiation dose reduction to 30 Gy: A novel de-escalation paradigm for HPV-associated oropharynx cancers1R01CA238392-01A1 · under PAR-18-560 | LEE, NANCY Y | SLOAN-KETTERING INST CAN RESEARCH, NY | $716,756 | RTB |
| 2020 | Conformal Total Body and Marrow Irradiation for Leukemia2R01CA154491-07A1 · under PAR-18-560 | HUI, SUSANTA KWONG, JEFFREY Y | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $708,512 | RTB |
| 2020 | Efficacy and immune effects of anakinra prophylaxis for neurologic toxicity and cytokine release syndrome in patients with lymphoma receiving axicabtagene ciloleucel1R01CA252940-01 · under PAR-18-560 | MAUS, MARCELA VALDERRAMA | MASSACHUSETTS GENERAL HOSPITAL, MA | $697,200 | CONC |
| 2020 | Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR)1U01CA238444-01A1 · under PAR-18-560 | CERCEK, ANDREAIACOBUZIO-DONAHUE, CHRISTINE AJARNAGIN, WILLIAM ROBERT | SLOAN-KETTERING INST CAN RESEARCH, NY | $682,721 | CONC |
| 2020 | Tailoring CAR T cell therapy for Hodgkin Lymphoma1R01CA247497-01A1 · under PAR-18-560 | SAVOLDO, BARBARA | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $634,693 | CONC |
| 2020 | Pneumatic Drill and Robot for MRI-Guided Pediatrics Long Bone Biopsy1R01CA248191-01 · under PAR-18-560 | CLEARY, KEVIN R.SHARMA, KARUN V | CHILDREN'S RESEARCH INSTITUTE, DC | $631,110 | IGIS |
| 2020 | Modulation of Tumor Microenvironment for Improved Therapy of Pancreatic Cancer1R01CA247471-01 · under PAR-18-560 | BATRA, SURINDER K.JAIN, MANEESHSALGIA, RAVI | UNIVERSITY OF NEBRASKA MEDICAL CENTER, NE | $614,511 | CONC |
| 2020 | Correlative biomarkers of IL-6 blockade combined with checkpoint inhibition1R01CA244936-01A1 · under PAR-18-560 | WEBER, JEFFREY S | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $610,766 | CBSS |
| 2020 | Fluorescence-guided resection of breast tumors using a topically-applied molecular probe1R01CA246678-01 · under PAR-18-560 | BASILION, JAMES PETER | CASE WESTERN RESERVE UNIVERSITY, OH | $595,998 | IPCA |
| 2020 | Quantitative PET Imaging of Hepatocellular Carcinoma (HCC)1R01CA239694-01A1 · under PAR-18-560 | MANNING, HENRY CHARLES | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $585,790 | CTIS |
| 2020 | Novel Methods of Chemo-sensitizing Low-proliferative Disseminated Tumor Cells in Triple Negative Breast Cancer1R01CA238387-01A1 · under PAR-18-560 | TRAN, DAVID D | UNIVERSITY OF FLORIDA, FL | $521,764 | CONC |
| 2020 | Understanding Richter's Transformation in the targeted therapies era1R01CA240493-01A1 · under PAR-18-560 | LAPALOMBELLA, ROSA | OHIO STATE UNIVERSITY, OH | $474,404 | CONC |
| 2020 | Phase I/II clinical trial of HDAC inhibition for GVHD prevention in children, adolescents, and young adults1R01CA249211-01 · under PAR-18-560 | CHOI, SUNG WON | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $466,089 | CONC |
| 2020 | Microbubble Cavitation for Improving Hepatocellular Carcinoma Radioembolization1R01CA238241-01A1 · under PAR-18-560 | EISENBREY, JOHNSHAW, COLETTE | THOMAS JEFFERSON UNIVERSITY, PA | $454,127 | RTB |
| 2020 | Targeting Focal Adhesion Kinase to Improve RT-inducted Tumor Immunity1R01CA248917-01 · under PAR-18-560 | DENARDO, DAVID GKIM, HYUNSCHWARZ, JULIE KRISTINA | WASHINGTON UNIVERSITY, MO | $453,504 | RTB |
| 2020 | [18F]-AraG -PET imaging to evaluate immunological response to checkpoint inhibitor therapy (CKI) in patients with advanced solid tumors1R01CA240638-01A1 · under PAR-18-560 | KUMMAR, SHIVAANIMARI APARICI, CARINA | STANFORD UNIVERSITY, CA | $423,444 | CTIS |
| 2020 | Blood-brain barrier disruption with implantable ultrasound to enhance paclitaxel delivery: A Phase 1-2 clinical trial in recurrent glioblastoma1R01CA245969-01A1 · under PAR-18-560 | SONABEND, ADAM MSTUPP, ROGER | NORTHWESTERN UNIVERSITY AT CHICAGO, IL | $419,323 | CONC |
| 2020 | Molecular Phenotyping and Image-Guidance for Surgical Treatment of High-Risk Prostate Cancer Using Ultrasmall Silica Nanoparticles1R01CA243085-01A1 · under PAR-18-560 | BRADBURY, MICHELLE STOUIJER, ABDELKRIM K.WIESNER, ULRICH | SLOAN-KETTERING INST CAN RESEARCH, NY | $396,582 | IGIS |
| 2020 | Small Molecule PSMA-Targeted Alpha Therapy2R01CA184228-06 · under PAR-18-560 | POMPER, MARTIN GZALUTSKY, MICHAEL ROD | JOHNS HOPKINS UNIVERSITY, MD | $319,250 | IPCA |
| 2020 | Developing BRAF mutant and BRAF wild-type selective strategies for radiosensitization in Anaplastic Thyroid Cancer1R01CA246553-01A1 · under PAR-18-560 | SHAH, MANISHA HWILLIAMS, TERENCE MARQUES | OHIO STATE UNIVERSITY, OH | $193,780 | MCE |
| 2020 | CD38-targeted immunoPET of myeloma: Phase 2 trial of clinical applications1R01CA248398-01 · under PAR-18-560 | LANDGREN, CARL OLAULANER, GARY ALLAN | SLOAN-KETTERING INST CAN RESEARCH, NY | $135,622 | IGIS |
| 2019 | A phase I/II combination immunotherapy clinical trial: mesothelin-targeted chimeric antigen receptor T cells and checkpoint blockade agent in pleural mesothelioma1R01CA235667-01A1 · under PAR-18-560 | ADUSUMILLI, PRASAD S.ZAUDERER, MARJORIE G. | SLOAN-KETTERING INST CAN RESEARCH, NY | $727,344 | CONC |
| 2019 | Targeting Alterations of the NOTCH1 Pathway in Head & Neck Squamous Cell Carcinoma (HNSCC)1R01CA235620-01A1 · under PAR-18-560 | FREDERICK, MITCHELL J.JANKU, FILIPJOHNSON, FAYE | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $666,259 | CONC |
| 2019 | Clinical evaluation of IL13Ra2-targeted CAR T cell therapy in combination with nivolumab in patients with recurrent malignant glioma1R01CA236500-01 · under PAR-18-560 | BADIE, BEHNAMBROWN, CHRISTINE | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $665,839 | CII |
| 2019 | Clinical Development of Rhenium Nanoliposomes (RNL186) for Glioblastoma1R01CA235800-01A1 · under PAR-18-560 | BRENNER, ANDREW JACOB | UNIVERSITY OF TEXAS HLTH SCIENCE CENTER, TX | $660,911 | CONC |
| 2019 | Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER)1R01CA235681-01A1 · under PAR-18-560 | HAHN, NOAH M | JOHNS HOPKINS UNIVERSITY, MD | $656,816 | CONC |
| 2019 | Application of Hyperpolarized 13C Magnetic Resonance Imaging to Detect Target Inhibition of NF-kB Activation and Response in Primary CNS Lymphoma1R01CA239462-01A1 · under PAR-18-560 | CHAUMEIL, MYRIAM MARIANNERUBENSTEIN, JAMES LOUIS | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $650,020 | CONC |
| 2019 | Multi-site adaptive trial of a technology-based, EHR-integrated physical activity intervention in breast and endometrial cancer survivors1R37CA225877-01A1 · under PAR-18-560 | CADMUSBERTRAM, LISA ANNEPHILLIPS, SIOBHAN MARIE | UNIVERSITY OF WISCONSIN-MADISON, WI | $646,190 | ZCA1 |
| 2019 | Phase one clinical trial of a novel small molecule EBNA1 inhibitor, VK-2019, in patients with Epstein- Barr positive nasopharyngeal cancer, with pharmacokinetic and pharmacodynamic correlative studies1R01CA235633-01 · under PAR-18-560 | COLEVAS, A. DIMITRIOS | STANFORD UNIVERSITY, CA | $629,493 | CONC |
| 2019 | Advanced PET-CT Directed Post-Prostatectomy Radiotherapy to Enhance Prostate Cancer Outcomes1R01CA226992-01A1 · under PAR-18-560 | JANI, ASHESHSCHUSTER, DAVID MICHAEL | EMORY UNIVERSITY, GA | $629,419 | RTB |
| 2019 | Targeting Neoantigens in Triple Negative Breast Cancer1R01CA240983-01 · under PAR-18-560 | GILLANDERS, WILLIAM E.SCHREIBER, ROBERT DAVID | WASHINGTON UNIVERSITY, MO | $629,038 | CONC |
| 2019 | Optical Imaging to Improve Surgery & Targeted Therapy in Brain Tumors1R01CA239257-01A1 · under PAR-18-560 | LI, GORDONROSENTHAL, EBEN L. | STANFORD UNIVERSITY, CA | $626,189 | IGIS |
| 2019 | Adoptive T Cell Therapy for Pancreatic Cancer1R01CA237672-01 · under PAR-18-560 | YEE, CASSIAN | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $623,803 | CII |
Showing the 200 most recent of 216 awards.
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.